A flagship clinical trial of Echo IQ’s (ASX: EIQ) EchoSolv artifical intelligence (AI) medical software technology has identified 72% more patients with severe aortic stenosis than human diagnosis alone.
Sydney-based medical technology company Echo IQ (ASX: EIQ) has confirmed its flagship structural heart disease screening platform EchoSolv is now available to registered customers in the US.
Heart disease diagnosis innovator Echo IQ (ASX: EIQ) has achieved a “step change in commercial readiness” in progressing its artificial intelligence (AI) based technology for the US market.